List view / Grid view
University of Houston researchers have identified a key cellular pathway involved in muscle wasting caused by pancreatic cancer, offering new insights into potential therapies.
Scientists in Japan have identified a way to weaken the dense fibrotic barrier that prevents drugs from penetrating pancreatic tumours – a promising new strategy that could improve treatment for pancreatic cancer.
What if RNA medicines could be guided directly to tumours, sparing healthy tissue and reducing side effects? Advances in targeted delivery are bringing that vision closer to reality.
A novel CAR-NKT immunotherapy developed at UCLA has shown striking success in preclinical models of metastatic pancreatic cancer, which could hopefully lead to more accessible treatments.
Researchers have discovered that pancreatic tumours evade the immune system by disguising themselves with a sugar coating. To combat this, they have developed a new antibody therapy that blocks this ‘don’t-attack’ signal, which slows tumour growth.
Drug discovery is slow, costly and often unsuccessful. DTR hears how GATC Health is applying AI and multiomics to make the process faster, more precise and less reliant on trial and error.
Scientists at Virginia Tech’s Fralin Biomedical Research Institute have identified a promising drug target – PRMT5 – that could make treatment-resistant lung, brain and pancreatic cancers more vulnerable to therapy.
Standard antibody therapies bind their target and trigger a response. But what if the real breakthrough is designing antibodies that first recognise context before they act? This article looks at how bispecifics are becoming smarter, more selective and more precise.
Researchers at the University of Michigan have discovered a powerful combination therapy that eradicates pancreatic tumours in preclinical models, offering hope for new treatments against one of the most treatment-resistant cancers.
A breakthrough in molecular imaging could transform how doctors target solid tumours, offering more personalised and effective treatment options.
Researchers have uncovered a how INPP4B, alongside PIKfyve and TRPML-1, drives pancreatic cancer metastasis.
The model enables researchers to expand the number of tumours that they can study, increasing their ability to detect novel interactions.
The humanised antibody, Hv1Lt1, showed promising results in pancreatic cancer mouse models.
The discovery that eFT508 blocks eIF4E and the ketogenic pathway could provide the foundation for personalised therapies.
Researchers have discovered that pancreatic cancer’s resistance to chemotherapy is related to the physical stiffness of the extracellular matrix.
